Aprea Therapeutics Files 8-K
Ticker: APRE · Form: 8-K · Filed: Oct 15, 2025 · CIK: 1781983
| Field | Detail |
|---|---|
| Company | Aprea Therapeutics, Inc. (APRE) |
| Form Type | 8-K |
| Filed Date | Oct 15, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing
Related Tickers: APRE
TL;DR
APRE filed an 8-K on 10/15/25, but it's light on details.
AI Summary
Aprea Therapeutics, Inc. filed an 8-K on October 15, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific details about the nature of these events or financial statements, only that they were reported on this date.
Why It Matters
This 8-K filing indicates that Aprea Therapeutics has made a regulatory submission, but without further details, its immediate impact on investors or the company's operations is unclear.
Risk Assessment
Risk Level: low — The filing is a standard 8-K reporting form without specific material events disclosed, making it low risk.
Key Players & Entities
- Aprea Therapeutics, Inc. (company) — Registrant
- October 15, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of incorporation
- 3805 Old Easton Road (address) — Principal executive offices
- Doylestown, PA (location) — City, State of principal executive offices
- 18902 (zip_code) — Zip code of principal executive offices
- 215-948-4119 (phone_number) — Registrant's telephone number
FAQ
What specific "Other Events" are being reported by Aprea Therapeutics in this 8-K?
The provided text does not specify the nature of the "Other Events" reported in the 8-K filing.
What are the key details of the "Financial Statements and Exhibits" mentioned in the 8-K?
The filing indicates that "Financial Statements and Exhibits" are part of the 8-K, but no specific details or content of these statements are provided in the text.
What is the significance of the filing date October 15, 2025?
October 15, 2025, is the date of the report and the earliest event reported by Aprea Therapeutics, Inc.
Where are Aprea Therapeutics, Inc.'s principal executive offices located?
Aprea Therapeutics, Inc.'s principal executive offices are located at 3805 Old Easton Road, Doylestown, PA 18902.
What is the Commission File Number for Aprea Therapeutics, Inc.?
The Commission File Number for Aprea Therapeutics, Inc. is 001-39069.
Filing Stats: 492 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-10-15 08:05:17
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share APRE The Nasdaq Stock Mar
Filing Documents
- apre-20251015x8k.htm (8-K) — 39KB
- apre-20251015xex99d1.htm (EX-99.1) — 22KB
- apre-20251015xex99d2.htm (EX-99.2) — 34KB
- apre-20251015xex99d1001.jpg (GRAPHIC) — 5KB
- apre-20251015xex99d1002.jpg (GRAPHIC) — 4KB
- apre-20251015xex99d2g001.jpg (GRAPHIC) — 126KB
- apre-20251015xex99d2g002.jpg (GRAPHIC) — 260KB
- apre-20251015xex99d2g003.jpg (GRAPHIC) — 95KB
- apre-20251015xex99d2g004.jpg (GRAPHIC) — 123KB
- apre-20251015xex99d2g005.jpg (GRAPHIC) — 166KB
- apre-20251015xex99d2g006.jpg (GRAPHIC) — 84KB
- apre-20251015xex99d2g007.jpg (GRAPHIC) — 168KB
- apre-20251015xex99d2g008.jpg (GRAPHIC) — 111KB
- apre-20251015xex99d2g009.jpg (GRAPHIC) — 65KB
- apre-20251015xex99d2g010.jpg (GRAPHIC) — 169KB
- apre-20251015xex99d2g011.jpg (GRAPHIC) — 181KB
- apre-20251015xex99d2g012.jpg (GRAPHIC) — 138KB
- apre-20251015xex99d2g013.jpg (GRAPHIC) — 84KB
- apre-20251015xex99d2g014.jpg (GRAPHIC) — 135KB
- apre-20251015xex99d2g015.jpg (GRAPHIC) — 89KB
- apre-20251015xex99d2g016.jpg (GRAPHIC) — 158KB
- apre-20251015xex99d2g017.jpg (GRAPHIC) — 138KB
- apre-20251015xex99d2g018.jpg (GRAPHIC) — 93KB
- apre-20251015xex99d2g019.jpg (GRAPHIC) — 161KB
- apre-20251015xex99d2g020.jpg (GRAPHIC) — 190KB
- apre-20251015xex99d2g021.jpg (GRAPHIC) — 147KB
- 0001104659-25-099534.txt ( ) — 4184KB
- apre-20251015.xsd (EX-101.SCH) — 3KB
- apre-20251015_def.xml (EX-101.DEF) — 3KB
- apre-20251015_lab.xml (EX-101.LAB) — 16KB
- apre-20251015_pre.xml (EX-101.PRE) — 11KB
- apre-20251015x8k_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On October 15, 2025, Aprea Therapeutics, Inc. (the "Company") issued a press release announcing the recommended Phase 2 dosing for ATRN-119, the pausing of further enrollment in both once daily and twice daily dosing arms of ABOYA-119 and its consideration of further ATRN-119 development in combination therapies. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference. On October 15, 2025, the Company also updated its corporate presentation slide deck. A copy of the corporate presentation slide deck is filed as Exhibit 99.2 hereto and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Press release dated October 15, 2025. 99.2 Corporate Presentation (October 2025). 104 Cover Page Interactive Data File (embedded within the inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aprea Therapeutics, Inc. Dated: October 15, 2025 By: /s/ Oren Gilad Name: Oren Gilad, Ph.D. Title: President and Chief Executive Officer